GlassScriptPhysician profile
Omid Dardashti
NPI 1639295686
$3,194.35
in general payments reported to CMS, 2019-2025
26 companies · $142 in 2025
The $142 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $365 · 2020: $94.33 · 2021: $360 · 2022: $1,283 · 2023: $365 · 2024: $584 · 2025: $142.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $927 · Education: $164.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $927.13 |
| Education | $163.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $538.34 | 2019-2025 | Watchman Flx |
| Novartis Pharmaceuticals Corporation | $351.79 | 2021-2024 | |
| Pfizer INC. | $269.47 | 2020-2024 | |
| Edwards Lifesciences Corporation | $197.44 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $191.34 | 2019-2024 | Brilinta, Andexxa, Farxiga |
| Merck Sharp & Dohme LLC | $172.56 | 2021-2023 | Verquvo, Steglatro |
| Amgen INC. | $163.73 | 2019-2024 | Repatha |
| Janssen Pharmaceuticals, INC | $161.75 | 2019-2024 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $153.54 | 2019-2025 | Camzyos, Eliquis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $143.06 | 2020-2024 | Jardiance |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $124.98 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $115.03 | 2020-2023 | Livalo |
| Cvrx, INC. | $106.74 | 2022-2024 | Barostim Neo System |
| Abiomed | $87.30 | 2024 | |
| Heartflow, INC. | $82.83 | 2022-2024 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $74.19 | 2019-2021 | |
| Amarin Pharma, INC. | $56.94 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $37.42 | 2021-2022 | |
| Arbor Pharmaceuticals, INC. | $28.29 | 2019 | |
| Sanofi-Aventis U.S. LLC | $27.49 | 2019-2022 | |
| Impulse Dynamics (USA) INC. | $23.65 | 2022 | |
| Irhythm Technologies, INC. | $20.96 | 2021 | |
| Actelion Pharmaceuticals US, INC. | $18.08 | 2024 | Opsumit |
| Scpharmaceuticals INC. | $17.15 | 2024 | |
| Kiniksa Pharmaceuticals International, Plc | $16.78 | 2024 | Arcalyst |
| Regeneron Healthcare Solutions, INC. | $13.50 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Omid Dardashti listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.